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Objectives: (1) To evaluate the number of opioid/benzodiazepine (BZD) prescription changes
resulting from pharmacist communication to prescriber(s); (2) to determine the number of
patients on concurrent opioid/BZD therapy from single versus multiple prescribers; (3) to
compare the number of opioid/BZD prescription changes resulting from communication when
a single versus multiple prescribers was involved in a patient’s care; and (4) to compare the
number of opioid/BZD prescription changes resulting from communication via fax versus the
Kansas Health Information Network (KHIN) direct messaging feature.
Methods: Prospective study conducted at 13 community pharmacies, including patients 18
years of age or older simultaneously filling opioid and BZD prescriptions within 90 days before
October 2017. Prescribers received faxed or KHIN communication proposing evidence-based
prescription changes to opioid/BZD agents. Prescription changes were evaluated weekly for
3 months after the initial intervention. Descriptive statistics assessed demographics and the
number and types of prescription changes. Spearman rho correlations compared prescription
changes and number of prescriptions to number of prescribers; a priori alpha was set at 0.05.
Results: A total of 137 prescribers and 121 patients were included. Ninety-nine prescribers
were contacted via fax and 38 via KHIN. After 4 weeks, 34 recommendations were received: 20
responses (59%) indicated rejection of recommendations, 5 (15%) approved BZD taper/
discontinuation, 3 (9%) deferred changes until a patient visit, 2 (6%) approved opioid taper/
discontinuation, 2 (6%) prescribed naloxone, and 2 (6%) withdrew from the patient’s care.
Three months after communication, 35 prescription changes were noted: 22 (63%) opioid/BZD
agent tapers/discontinuation, 14 (26%) opioid/BZD dose increases, and 2 (6%) naloxone pre-
scriptions. There was positive correlation between the number of tapered/discontinued agents
and the number of prescribers involved in a patient’s care (P ¼ 0.046).
Conclusion: A faxed pharmacist intervention may help to reduce opioid/BZD coprescribing,
especially when multiple providers are involved in a patient’s care.
© 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.Drug misuse or abuse is a critical issue in the United States,
leading to steady increases in emergency department (ED)
visits.1 Opioid overdose deaths doubled from 2015 to 2016
from 3.1 to 6.2 per 100,000 people.2 Moreover, opioids and
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To address the issue of drug misuse, and to aid clinicians in
the prescribing of high-risk medications, the Centers for
Disease Control and Prevention (CDC) published an evidence-
based guideline on opioid prescribing for chronic pain in
2016.4 The guideline outlines the risks of coprescribing opioids
with BZDs and encourages clinicians to openly discuss the
risks of the combination with patients or to avoid copre-
scribing whenever possible.
Subsequently, the Pharmacy Quality Alliance (PQA) devel-
oped several measures involving medications associated with
a high risk for overdose. Specifically, newmeasures address (1)
opioids from multiple prescribers and (2) concurrent use of
opioids and BZDs.5 The pharmacist role in monitoring medi-
cation prescribing patterns was also highlighted in a studync. All rights reserved.
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indicated that a higher number of prescribers was associated
with a higher number of drug interactions and suggested that
pharmacists could play a role in reducing drug interactions.6
Few studies have examined the impact of pharmacist
interventions on opioid and BZD coprescribing, and most were
in specialized settings. A retrospective study examined the
impact of pharmacy consultations on opioid and BZD copre-
scribing in a veteran population and found a reduction in the
coprescribing practices and overdose-related events.7 Simi-
larly, a pilot study assessed the impact of a pharmacist previsit
consultation on high-risk patients treated with opioids in a
family medicine clinic. Using the CDC guidelines for pharma-
cist recommendations, it reduced opioid use and decreased
opioid and BZD coprescribing.8 Despite some encouraging
results regarding pharmacists’ impact in reducing copre-
scribing of opioids and BZDs, to date no studies have been
conducted in community pharmacies.
Although community pharmacies may not have direct
access to electronic health records (EHRs), tools such as state-
level health information exchange (HIE) programs could
facilitate transmission of patient care recommendations. A
number of studies evaluated the use of HIEs in the United
States, finding that clinicians’ perception of benefits of the
platform depends on the data availability and workflow inte-
gration.9,10 The Kansas Health Information Network (KHIN), is
regarded as one of the most functional HIEs in the United
States,11,12 with robust statewide participation that provides a
sizeable volume of available patient data from 126 hospitals
and 75% of the state’s physician practices. In addition, users,
including pharmacists, are able to collaborate with one
another via a direct messaging feature. To date, use of the KHIN
messaging feature by community pharmacists and providers
has not been studied. Currently, Balls Food Stores (BFS) com-
munity pharmacists use faxing as a standard interprofessional
communication tool concerning medication recommenda-
tions that are not of immediate concern.
The present study sought to examine the impact of
pharmacist intervention on reducing opioid and BZD copre-
scribing and to evaluate the comparative effectiveness of tools
designed to facilitate interdisciplinary communications.Objectives
The objectives were to (1) evaluate the number of opioid/
BZD prescription changes resulting from pharmacist commu-
nication to the prescriber(s); (2) determine the number of
patients on concurrent opioid/BZD therapy from single versus
multiple prescribers; (3) compare the number of opioid/BZD
prescription changes resulting from communication when a
single versus multiple prescribers was involved in a patient’s
care; (4) compare the number of opioid/BZD prescription
changes resulting from communication via fax versus the
KHIN messaging feature.Methods
This prospective study used dispensing records from 13
Kansas pharmacies within BFS, a supermarket chain in the
Kansas City metropolitan area.Eligible patients were 18 years of age or older and had
received 1 or more oral opioid and BZD agents in the 90 days
before October 1, 2017. Inclusion and exclusion criteria were
derived from the PQA measure related to concurrent use of
opioids and BZDs.5 Included participants had concurrent
active prescriptions for opioids and BZDs for 30 or more
cumulative days in the past 90 days. Patients receiving hospice
care or who had cancer-related diagnoses were excluded.
Prescriber and patient data, including demographics and
prescription data, were collected from the patient’s dispensing
record by a single pharmacist and verified by a second
pharmacist for accuracy. Discrepancies were discussed and
subsequently corrected.
After identifying the study sample, patients’ prescribers
were contacted if they had prescribed an opioid or BZD agent
for a supply of 7 or more days. The 7-day supply limitationwas
implemented to avoid contacting prescribers not regularly
involved in the patient’s care and those who prescribed
opioids only for acute pain management.4
Both the fax and KHIN communications included identical
written information comprising (1) a letter introducing the
study purpose and relevant clinical guidelines; (2) patient
dispensing records, including the name, dose, and days’ supply
of the last 3 fills for each opioid and BZD agent, as well as
names of other prescribers who had prescribed any opioid or
BZD agents; and (3) a set of standardized recommendations.
The prescriber was asked to select 1 or more of the suggested
recommendations and return the response to the pharmacy.
The recommendations were derived from the CDC guidelines
for prescribing opioids for chronic pain and included options
for tapering or discontinuing the opioid or BZD agent(s),
replacing the agent(s), prescribing naloxone, declining any
action, or providing alternate suggestions or comments.4
Communications were sent once per week, for up to 3
weeks, until a response was received. The methods of
communication were not altered after stratification, even if no
responses were received, to ensure that data would be an
accurate reflection of the fax or KHIN effectiveness. Faxed
responses were collected from each participating pharmacy at
1-week intervals after the communication delivery to allow
time for prescribers to respond to the request. Electronic re-
sponses from KHIN were collected at the same time as fax
responses via platform access. Three months after the initial
communication, dispensing records of each study patient were
reviewed to record medication changes related to opioid or
BZD agents or receipt of a naloxone prescription. This phar-
macy records review ensured that all relevant prescription
changes were captured, even if a response to the standardized
recommendations was not directly communicated by the
prescriber. The 3-month time frame was selected because
Kansas regulations allow up to a 3-month supply on any
schedule II prescription. A positive medication change was
defined as tapering or discontinuing an opioid or BZD agent.
Data analysis was conducted with the use of SPSS v. 24.
Descriptive statistics were used to assess patient and provider
demographics and determine the number and types of
prescription changes. Chi-square was used to compare de-
mographics for KHIN versus non-KHIN providers. Spearman
rho correlations compared the number of prescription changes
with the number of providers involved in the patient’s care, as
well as the number of prescriptions per patient with the239
Table 1
Demographics of patients, included in the study owing to concurrent use of
opioid and benzodiazepine (BZD) agents, and prescribers involved in the pa-
tients’ care, n (%)
Patient parameters (n ¼ 121)
Female sex 81 (67)
Age (y), median (IQR) 62 (52e69.5)




Yes (n ¼ 38; 28%) No (n ¼ 99; 72%)
Sex
Femalea 20 (53) 27 (27)
Male 18 (47) 72 (73)
Prescriber type
Physician prescriber 35 (92) 87 (88)
Mid-level prescriber 3 (8) 12 (12)
Abbreviations used: IQR, interquartile range; KHIN, Kansas Health Informa-
tion Network.
a Statistically significant difference (P ¼ 0.005).
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SCIENCE AND PRACTICEnumber of prescribers involved in the patient’s care. Statistical
significance was defined as P  0.05.
This study was granted exempt status from the University
of Kansas Medical Center Human Research Protection
Program.Results
A study population of 3974 unique patients was identified.
One hundred twenty-two patients met the inclusion criteria,
and 1 patient was excluded owing to a cancer diagnosis.
Patients received 1 or more prescriptions from 149 unique
prescribers during the study period.
After limiting contact to those who had prescribed more
than a 7-day supply of either agent, 137 prescribers were
included in the study. Of these, 38 had an active KHIN account
and were contacted via the KHIN secure messaging feature.
The remaining 99 prescribers were contacted via fax. Seven-
teen of the 38 KHIN messages failed to be delivered; KHIN
technical support was unable to provide resolution for delivery
failure. Demographics for both patients and prescribers are
presented in Table 1.
A total of 32prescribers responded to thepharmacist’s faxed
communication during the initial 4-week period, providing 34
unique responses (1 prescribermade 2 recommendations for 1
patient, and another made recommendations for 2 separate
patients). Details regarding the number and type of responses
received each week following the pharmacist communication
are presented in Table 2.
The pharmacy records review that occurred 3 months after
the intervention identified 35 prescription changes, corre-
sponding to 29 of 122 unique patients. One or more positive
changes were observed for 19 unique study patients (16%), and
a dose increase of either the opioid or BZD agent was observed
for 9 unique patients (7%). A request for clinical rationale was
not elicited from each prescriber, although some prescribers
volunteered information. One prescriber indicated that the
BZD agent was prescribed for seizures, warranting the BZD
dose increase. In 2 patients the prescriber tapered or
discontinued the opioid but increased the BZD dose. A detailed
description of provider responses and prescription changes is240presented in Table 2. No responses were received from pre-
scribers contacted via KHIN; however, 4 prescription changes
were observed at the 3-month follow-up. Three changes were
positive, and the other was an opioid dose increase.
There was a statistically significant positive correlation be-
tween the number of positive prescription changes and the
number of prescribers involved in a patient’s care, indicating
thatmorepositive changes occurredwhenmultiple prescribers
were involved in a patient’s care (r ¼ 0.182; P ¼ 0.046). In
addition, a higher number of opioid or BZD prescriptions were
observed when more than 1 prescriber was involved in the
patient’s care (r ¼ 0.386, 0.325, and 0.391, respectively for
opioids, BZD, and total prescriptions; P < 0.001).Discussion
Pharmacists are increasingly called on to address the opioid
epidemic and reduce opioid/BZD coprescribing.5 Little is
known about community pharmacist impact on opioid pre-
scribing trends or the best methods for interdisciplinary
communication. To the authors’ knowledge, this is the first
study to examine multiple communication approaches to
influence opioid and BZD prescribing patterns in the com-
munity pharmacy setting.
In this study, the majority of prescription changes (63%)
that occurred after pharmacist intervention resulted in
tapering or discontinuation of the opioid or BZD agent. These
observations are consistent, though less marked, with findings
from research conducted in different practice settings.7,8 Pardo
et al. found a 35% reduction in opioid and BZD coprescribing
after implementation of a prior authorization pharmacist
consult in the veteran population,7 compared with 16% in the
present study. Notably, pharmacists in the Pardo et al. study
were integrated in the Veterans Affairs Health Care System,
and prescribers were required to acknowledge the pharmacist
consultation before sending the prescription. In contrast, there
was noway to verify receipt of the communication provided in
the present study. In addition, BFS pharmacists were not
contractually affiliated with any of the prescribers contacted,
possibly contributing to the lower observed response rate.
Reduction in coprescribing of opioids and BZDs was also
observed in another study performed at a family medicine
residency clinic.8 Clinic pharmacists reviewed patient charts
before the prescriber visits and documented recommenda-
tions in the patient’s EHR. Similarly to the present study, in
addition to the opioid/BZD coprescribing reduction, pharma-
cists also focused on recommending naloxone initiation. A
total of 37 naloxone prescriptions were recommended by
clinic pharmacists, and 20 were offered by the prescribers. In
our study, naloxone was recommended as an option for all
patients, but only 2 prescriptions were furnished. The lower
number of naloxone prescriptions dispensed in this study
compared with the one conducted by Cox et al. could be
explained by the fact that in Cox’s study, pharmacists provided
individualized recommendations within the patient’s EHR,
which were available during the patient’s visit with the pre-
scriber. in contrast, the present study encouraged naloxone
prescribing as part of a standardized list. As a result, pre-
scribers did not have immediate electronic access to the
community pharmacist’s recommendation during the patient
visit. Furthermore, this study did not have a method of
Table 2
Type and number (%) of prescriber responses and prescription changes that occurred after the pharmacist communication




Week 1 Week 2 Week 3 Week 4 Total responses
Declined all recommendations 10 (67) 4 (50) 3 (43) 3 (75) 20 (59) NA
BZD taper or discontinuation 3 (20) e 1 (14) 1 (25) 5 (15) 11 (31)
Deferred to patient-prescriber visit e 2 (25) 1 (14) e 3 (9) NA
Opioid taper or discontinuation 2 (13) e e e 2 (6) 11 (31)
Prescriber discontinued care e e 2 (28) e 2 (6) 2 (6)
Naloxone prescribed e 2 (25) e e 2 (6) 2 (6)
Opioid dose increase e e e e e 5 (14)
BZD dose increase e e e e e 4 (11)
Total 15b 8 7 4 34 35c
Abbreviations used: BZD, benzodiazepine; NA, not applicable.
a Percentages may not equal 100% owing to rounding.
b Two prescribers provided more than 1 response. One prescriber declined the recommendation for 1 of his patients but discontinued the BZD for his other
patient. Another prescriber both tapered the BZD and stopped the opioid agent.
c Changes were observed even in patients whose prescribers did not respond to the pharmacist communication. In addition, more than 1 change was observed
for 6 study patients (2 had an opioid reduction or discontinuation and a BZD dose increase, 3 had reduction or discontinuation in both the opioid and BZD agents,
and 1 had a BZD dose reduction and a provider who discontinued care).
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declined.
The positive correlation between the number of prescrip-
tion changes and number of prescribers involved in a patient’s
care highlights the role of community pharmacists in helping
promote transparency between providers, especially when
care is disjointed. Specifically, 2 prescribers chose to discon-
tinue care for the patient and defer to an alternate provider,
revealing they may have been unaware of the patient’s full
medication history or existence of additional prescribers. The
literature suggests that opioid prescribing by multiple pre-
scribers leads to higher hospitalization risks13 and that
collaboration between providers could improve coordination
of care.14 By raising awareness and promoting transparency,
pharmacists could be part of this collaboration, helping to
improve patient outcomes.
Finally, one of this study’s primary objectives was to
compare the number of prescription changes resulting from
communications sent via fax versus KHIN messaging. This
comparison was not possible, because no responses were
received from the KHIN prescriber cohort, and the number of
changes that occurred from KHIN prescribers at the 3-month
follow-up were too few to provide statistical comparison.
The low use of KHIN is in line with previous studies. A sys-
tematic review examining HIE use among health professionals
found that although HIE use has grown in the past 10 years, it
is primarily adopted by larger health systems. In addition,
comparisons among health professionals showed a greater use
of HIE by nurses and ED physicians.15 The present study’s
findings suggest that HIE use by individual prescribers for
interprofessional multi-institutional communication may be
more limited compared with internal health system use.
Overall, the study results align with the idea that commu-
nity pharmacists could influence opioid and BZD coprescribing
patterns, and they support faxing as a useful interprofessional
communication tool. Future studies examining a multimodal
approach (e.g., fax followed by a telephone call) for commu-
nicating interventions could be helpful in identifying more
effective methods for interprofessional collaboration. Finally,
studies involving a control arm without a pharmacistintervention could help to clarify which findings directly
resulted from the pharmacist communication.
Limitations
There were several limitations to this study. First, only oral
medications were studied. Second, the limited number of
providers with active KHIN accounts did not allow for study
randomization regarding intervention communication media.
Third, pilot messages were not sent to providers before the
study to ensure KHIN functionality, and when KHIN or fax
communications were sent, there was no method to confirm if
prescribers received the message. Fourth, the study used the
HIE platform unique to Kansas, so the findings may have
limited generalizability. Fifth, the study was conducted in a
short time frame, limiting the sample size. Sixth, fills at non-
study pharmacies were not examined. Finally, our study did
not include a control group, which could demonstratewhether
similar opioid and BZD prescription changes would occur
without a pharmacist intervention.
Conclusion
A faxed intervention from a community pharmacist may
help to reduce opioid/BZD coprescribing, especially when
multiple providers are involved in a patient’s care. In addition,
KHIN secure messaging was not found to be an effective me-
dium for communicating patient care recommendations from
the community pharmacy setting at this time.
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